MedTrace Logo

A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

NCT06620848 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-04-02

No results posted yet for this study

Summary

The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

HRS-4642 monotherapy

HRS-4642 will be administrated per dose level in which the patients are assigned.

DRUG

HRS-4642 and adebrelimab combination therapy

HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Jia Fan, M.D · Shanghai Zhongshan Hospital

  • Guoming Shi, M.D · Shanghai Zhongshan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-21
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06620848 on ClinicalTrials.gov